Is filgrastim the same as a peptide supplement?

No. It is a recombinant protein biologic (G-CSF) that requires a prescription and clinical monitoring; it is not a research chemical or over-the-counter supplement.

Why does filgrastim cause bone pain?

Bone pain reflects the marrow expanding neutrophil production; it is the most common side effect and is usually mild-to-moderate and manageable with analgesics.

How is filgrastim different from pegfilgrastim?

Filgrastim is short-acting and typically given as daily injections, while pegfilgrastim is a pegylated long-acting form usually given once per chemotherapy cycle.

What serious risks should patients know about?

Rare but serious risks include splenic rupture, acute respiratory distress syndrome, capillary-leak syndrome, and sickle-cell crises; any severe abdominal/shoulder pain or breathing difficulty needs urgent medical attention.

EMA-approved

Filgrastim — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Filgrastim is a peptide catalogued under Immune. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Filgrastim?

Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF), a 175-amino-acid protein produced in E. coli and marketed as Neupogen (with several approved biosimilars).

It is a prescription biologic first approved by the FDA in 1991 to reduce febrile neutropenia in patients receiving myelosuppressive chemotherapy, to shorten neutropenia after induction/consolidation for acute myeloid leukemia and after bone-marrow transplant, to mobilize peripheral-blood progenitor cells, and to treat severe chronic neutropenia.

Evidence is strong and human: efficacy rests on randomized controlled trials and systematic reviews, not preclinical data.

How does Filgrastim work?

Filgrastim binds the G-CSF receptor on neutrophil-lineage cells, driving proliferation, differentiation, and release of mature neutrophils from the bone marrow and enhancing their function.

This shortens the depth and duration of chemotherapy-induced neutropenia and mobilizes CD34+ progenitors into the circulation.

What does the research say about Filgrastim?

Prophylactic filgrastim roughly halved the incidence of chemotherapy-induced febrile neutropenia in patients with small-cell lung cancer. ^[1]
Primary G-CSF prophylaxis reduced febrile neutropenia and lowered early infection-related and all-cause mortality across adult chemotherapy trials in a systematic review. ^[4]
In severe chronic neutropenia, filgrastim raised neutrophil counts and reduced infections and antibiotic use in a randomized controlled trial. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer — Crawford J et al., New England Journal of Medicine 1991. (Randomized controlled trial)
[2] Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy — Trillet-Lenoir V et al., European Journal of Cancer 1993. (Randomized controlled trial)
[3] A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia — Dale DC et al., Blood 1993. (Randomized controlled trial)
[4] Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review — Kuderer NM et al., Journal of Clinical Oncology 2007. (Systematic review/meta-analysis)
[5] Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update — Smith TJ et al., Journal of Clinical Oncology 2015. (Clinical practice guideline)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Filgrastim is a clinician-prescribed injectable dosed by body weight and indication (for example weight-based daily dosing for chemotherapy-associated neutropenia versus higher regimens for progenitor-cell mobilization), with timing tied to the chemotherapy cycle.

This is background context only, not a dosing recommendation; administration is individualized and monitored by the treating hematology/oncology team with regular blood counts.

Side effects & safety profile

The most common adverse effect is medullary bone pain, typically mild-to-moderate and manageable with analgesics. Splenic enlargement occurs and splenic rupture, though rare, has been reported and can be fatal, so left-upper-quadrant or shoulder-tip pain warrants urgent evaluation.

Labeling carries warnings for acute respiratory distress syndrome (ARDS), capillary-leak syndrome, and sickle-cell crises in patients with sickle-cell disorders; allergic reactions can occur.

It should not be given in the 24 hours before through 24 hours after cytotoxic chemotherapy.

Stacking & combinations

In clinical practice filgrastim is used alongside cytotoxic chemotherapy regimens and, for stem-cell collection, is sometimes combined with plerixafor under specialist supervision, not as a self-directed stack.

Finding Filgrastim vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is FDA-approved to reduce febrile neutropenia in patients on myelosuppressive chemotherapy, to shorten neutropenia after AML induction/consolidation and after bone-marrow transplant, to mobilize peripheral-blood progenitor cells, and to treat severe chronic neutropenia.

References

[1] Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer — Crawford J et al., New England Journal of Medicine 1991. PMID: 1711156. View sourceStudy: Randomized controlled trialFilgrastim reduced the incidence, duration, and severity of chemotherapy-induced febrile neutropenia versus placebo.
[2] Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy — Trillet-Lenoir V et al., European Journal of Cancer 1993. PMID: 7691119. View sourceStudy: Randomized controlled trialFilgrastim lowered febrile neutropenia and infection-related complications during cytotoxic chemotherapy.
[3] A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia — Dale DC et al., Blood 1993. PMID: 8490166. View sourceStudy: Randomized controlled trialFilgrastim increased neutrophil counts and reduced infections in severe chronic neutropenia.
[4] Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review — Kuderer NM et al., Journal of Clinical Oncology 2007. PMID: 17634496. View sourceStudy: Systematic review/meta-analysisG-CSF primary prophylaxis reduced febrile neutropenia, infection-related mortality, and early all-cause mortality.
[5] Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update — Smith TJ et al., Journal of Clinical Oncology 2015. PMID: 26169616. View sourceStudy: Clinical practice guidelineDefines when prophylactic G-CSF (including filgrastim) is indicated based on febrile-neutropenia risk.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.